BioNTech

2 cancer biotechs merge, creating global footprint

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger.

Gabrielle Masson Sep 25, 2024 10:54am

Go sign green light

FDA allows BioNTech-MediLink ADC trial to resume at lower doses

Aug 19, 2024 8:45am

flu virus b cells influenza

Pfizer, BioNTech combo mRNA shot latest to lose to flu strain B

Aug 16, 2024 8:25am

illustration of two arrows going in opposite directions

BioNTech ends work on Genmab-partnered bispecific antibody

Aug 5, 2024 7:50am

Businessman jumping over hurdle - stock photo viafilmsGetty Images

BioNTech, Regeneron rack up response rate win for cancer vaccine

Jul 30, 2024 6:45am

FDA stop sign

FDA halts BioNTech ADC trial over 'significant risk of illness'

Jun 17, 2024 9:17am